Clinical Specialties Compounding Pharmacy Recalls Test Cyp 50 mg-estradiol Blend
Clinical Specialties Compounding Pharmacy is recalling Test Cyp 50 mg-estradiol blend 22 mg due to lack of assurance of sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, FDA Class II recalls involving significant injury/property-damage reports or structural defects are rated Severe (4). While no specific injuries are reported in the text, the 'lack of assurance of sterility' in a compounded drug represents a significant risk of serious harm (infection), aligning with the Severe classification for Class II recalls with potential for significant harm.
Plain-English summary
Clinical Specialties Compounding Pharmacy is recalling Test Cyp 50 mg-estradiol blend 22 mg, a 13ml total quantity product. The recall was initiated following FDA inspection findings that raised concerns regarding quality control processes, specifically resulting in a lack of assurance of sterility.
The affected products were distributed in Florida, Georgia, and South Carolina. The recall includes three specific lots: Lot number CABCAIBA:36 with an expiration date of 4/6/2013; Lot number CABDDAAB:10 with an expiration date of 7/29/2013; and Lot number CABDAIAD:01 with an expiration date of 9/4/2013.
Consumers who possess these specific lots of the product should stop using them and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Test Cyp 50 mg-estradiol blend 22 mg, Clinical Specialties Compounding Pharmacy, 318 Baston Road, Augusta, GA 30907
- Manufacturer
- Clinical Specialties Compounding Pharmacy
- Category
- Drug — Compounded Medication
- Affected units
- 13
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot number CABCAIBA:36
- Exp date: 4/6/2013
- Lot number CABDDAAB:10
- Exp date: 7/29/2013 and Lot number CABDAIAD:01 Exp date: 9/4/2013.
Distribution
Part of a larger recall action
This product is one of 49 recalled by Clinical Specialties Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 49 products in this recall →Related recalls
Same manufacturer · Clinical Specialties Compounding Pharmacy
See all →- SevereAvastin Syringes Recalled for Sterility Concerns and Eye Infection Reports
FDA (Drugs) · 2013-09-04
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 250 mg-lidocaine 5 mg/ml
FDA (Drugs) · 2013-07-10
- SevereEstradiol Cypionate Injection Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 200 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereClinical Specialties Compounding Pharmacy Recalls Test Cyp 100 mg/ml Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
Same hazard · sterility
See all →- SevereRegeneron Recalls Libtayo Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-08-26
- SeverePrestige Recalls Clear Eyes Maximum Itchy Eye Relief Due to Sterility Concerns
FDA (Drugs) · 2026-08-19
- SevereFDA Recalls ROHTO OPTIC GLOW Eye Drops Over Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29
- SevereROHTO Cooling Eye Drops Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2026-07-29